Despite excellent research outcomes in animal models, such as significant reductions in tau phosphorylation and Aβ formation, as well as the amelioration of spatial memory deficits, tideglusib was disqualified in phase II due to lack of efficacy in mild–moderate AD patients [28,29,30]. This evidence concerns the gene MAPT and Alzheimer disease.